FIELD: medicine; pharmaceuticals.
SUBSTANCE: first object is a composition for treating an infection caused by influenza virus containing from 1 to 400 mg ethyl-(3R,4R,5S)-5-amino-4-acetamido-3-(pentan-3-yloxy)-cyclohex-1-en-1-carboxylate (oseltamivir) as a neuraminidase inhibitor, 100 to 4000 mg clarithromycin as a macrolide antibiotic and from 5 to 200 mg of naproxen as non-steroid anti-inflammatory drug. Composition can additionally contain a proton pump inhibitor and an antibacterial antibiotic. 2–4 objects—corresponding applications and method of infection treatment, caused by influenza virus. 5 object is a corresponding kit for treating a disease caused by an influenza virus infection.
EFFECT: technical result consists in intensified antiviral action on influenza virus infections, neuraminidase inhibitor when administered together with a macrolide antibiotic and a non-steroid anti-inflammatory drug.
21 cl, 5 dwg, 8 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF ANTIVIRAL AGENTS FOR TREATING INFLUENZA VIRAL PNEUMONIA AND USE THEREOF | 2018 |
|
RU2703535C1 |
| COMPOSITION CONTAINING PEPTIDE AND VIRUS NEURAMINIDASE INHIBITOR | 2011 |
|
RU2596785C2 |
| MEFLOQUINE AND COMBINATIONS THEREOF FOR TREATING AND PREVENTING A CORONAVIRUS INFECTION | 2020 |
|
RU2763024C1 |
| ANTIVIRAL DRUG AS CAPSULES AND METHOD FOR ITS PREPARATION | 2014 |
|
RU2633085C2 |
| MAST CELL STABILIZERS FOR THE TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION | 2017 |
|
RU2760682C2 |
| USE OF LEVOCETIRIZINE AND MONTELUKAST IN TREATMENT OF TRAUMATIC INJURY | 2014 |
|
RU2672871C2 |
| MEANS FOR PREVENTION OF INTERSTITIAL PNEUMONIA | 2020 |
|
RU2747550C1 |
| METHOD FOR PREVENTION OR TREATMENT OF CORONAVIRUS AND OTHER ACUTE RESPIRATORY VIRAL INFECTIONS | 2022 |
|
RU2794315C1 |
| USING LEVOCETIRIZINE AND MONTELUKAST IN TREATING ANAPHYLAXIS | 2014 |
|
RU2705097C2 |
| LIQUID DOSAGE FORM FOR TREATING AND PREVENTING INFLUENZA AND SARS | 2020 |
|
RU2744854C1 |
